Biotech Stocks Pressured (BIIB) (CELG) (GILD)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to Biotech Stocks Pressured (BIIB) (CELG) (GILD)
April 27, 2015 7:38 AM EDT
uniQure (NASDAQ: QURE) declined in sympathy with Celadon Group (NASDAQ: CLDN) after Celadon announced that its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints.
Traders are also watching shares of gene therapy stocks Spark... More
April 27, 2015 7:19 AM EDT
Roth Capital downgraded Celladon Corp (NASDAQ: CLDN) from Buy to Neutral with a price target of $2.00.
For an analyst ratings summary and ratings history on Celladon Corp click here. For more ratings news on Celladon Corp click here.
Shares of Celladon Corp closed at $13.68 yesterday.
...
More
April 27, 2015 7:18 AM EDT
Wedbush downgraded Celladon Corp (NASDAQ: CLDN) from Outperform to Neutral with a price target of $3.00 (from $29.00) after the company announced Sunday that Mydicar failed to meet the primary and secondary endpoints in CUPID2.
Analyst David Nierengarten said they view further development of... More
April 27, 2015 6:34 AM EDT
Celladon Corporation (Nasdaq: CLDN) today announced that its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints. CUPID2 is a randomized, double-blind, placebo-controlled, multinational trial evaluating a single, one-time, intracoronary infusion of the cardiovascular gene therapy agent MYDICAR® (AAV1/SERCA2a) versus placebo added to a maximal, optimized heart failure drug and device regimen.
In the study, the primary endpoint comparison of MYDICAR to placebo resulted in a hazard ratio of 0.93 (0.53, 1.65 95%CI) (p=0.81),... More
